Cargando…

Incidence of Ipilimumab-Related Serious Adverse Events in Patients with Advanced Cancer: A Meta-Analysis

Background: Little is known about the incidence of ipilimumab-related serious adverse events (SAEs) across various tumor types, drug doses and treatment regimens. Methods: PubMed database was searched up to November, 2017 to identify prospective clinical trials of ipilimumab therapy for adult patien...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guo, Chang-Ying, Jiang, Si-Cong, Kuang, Yu-Kang, Hu, Hao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2019
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6329845/ https://www.ncbi.nlm.nih.gov/pubmed/30662532 http://dx.doi.org/10.7150/jca.28120

Ejemplares similares

Meta-analysis of incidence and risk of severe adverse events and fatal adverse events with crizotinib monotherapy in patients with ALK-positive NSCLC
por: Zhu, Qian, et al.
Publicado: (2017)

Risk of Adverse Events in Cancer Patients Receiving Nivolumab With Ipilimumab: A Meta-Analysis
por: Zhao, Xin, et al.
Publicado: (2022)

Ipilimumab in the treatment of metastatic melanoma: management of adverse events
por: Della Vittoria Scarpati, Giuseppina, et al.
Publicado: (2014)

Adverse events induced by nivolumab and ipilimumab combination regimens
por: Somekawa, Kohei, et al.
Publicado: (2022)

Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients: Nivolumab-related serious/fatal adverse events
por: Zhao, Bin, et al.
Publicado: (2018)

The safety and serious adverse events of approved ALK inhibitors in malignancies: a meta-analysis
por: Hou, Helei, et al.
Publicado: (2019)

Estimated Costs of the Ipilimumab–Nivolumab Therapy and Related Adverse Events in Metastatic Melanoma
por: Gautron Moura, Bianca, et al.
Publicado: (2022)

Serious Neurological Adverse Events of Ceftriaxone
por: Lacroix, Clémence, et al.
Publicado: (2021)

Adverse Events Following Administration of Anti-CTLA4 Antibody Ipilimumab
por: Karimi, Amirali, et al.
Publicado: (2021)

Real-World Incidence of Immune-Related Adverse Events Associated with Nivolumab Plus Ipilimumab in Patients with Advanced Renal Cell Carcinoma: A Retrospective Observational Study
por: Washino, Satoshi, et al.
Publicado: (2021)

Neurologic immune-related adverse events associated with adjuvant ipilimumab: report of two cases
por: Garcia, Christine A., et al.
Publicado: (2018)

Potential Immune-Related Adverse Events Associated With Monotherapy and Combination Therapy of Ipilimumab, Nivolumab, and Pembrolizumab for Advanced Melanoma: A Systematic Review and Meta-Analysis
por: Almutairi, Abdulaali R., et al.
Publicado: (2020)

Identification of serious, unpredictable adverse events with tocilizumab
Publicado: (2020)

Review of Immune-Related Adverse Events in Prostate Cancer Patients Treated with Ipilimumab: MD Anderson Experience
por: Gao, Jianjun, et al.
Publicado: (2015)

Risk of immune-related adverse events associated with ipilimumab-plus-nivolumab and nivolumab therapy in cancer patients
por: Zhou, Shi, et al.
Publicado: (2019)

SUN-414 Immune Related Adverse Events: Isolated ACTH Deficiency with Nivolumab/Ipilimumab Combination Therapy
por: Magdaleno, Angela, et al.
Publicado: (2019)

Serious adverse events associated with yellow fever vaccine
por: de Menezes Martins, Reinaldo, et al.
Publicado: (2015)

Analysis of serious adverse event: Writing a narrative
por: Nambiar, Indu
Publicado: (2018)

Correction to: Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients
por: Zhao, Bin, et al.
Publicado: (2019)

Serious haematological toxicity during and after ipilimumab treatment: a case series
por: Simeone, Ester, et al.
Publicado: (2014)

Evaluating cost per remission and cost of serious adverse events of advanced therapies for ulcerative colitis
por: Jairath, Vipul, et al.
Publicado: (2022)

Serious adverse events and coping strategies of CAR-T cells in the treatment of malignant tumors
por: Chen, Xiujin, et al.
Publicado: (2022)

Neurological Immune Related Adverse Events Associated with Nivolumab, Ipilimumab, and Pembrolizumab Therapy—Review of the Literature and Future Outlook
por: Möhn, Nora, et al.
Publicado: (2019)

Serious adverse events of cell therapy for respiratory diseases: a systematic review and meta-analysis
por: Zhao, Runzhen, et al.
Publicado: (2017)

Serious adverse events following treatment of visceral leishmaniasis: A systematic review and meta-analysis
por: Singh-Phulgenda, Sauman, et al.
Publicado: (2021)

Clinical picture and outcome of Serious Adverse Events in the treatment of Onchocerciasis
por: Awadzi, Kwablah
Publicado: (2003)

Influenza Vaccination of Pregnant Women and Serious Adverse Events in the Offspring
por: Donzelli, Alberto
Publicado: (2019)

Incidence and Risk Factors of Serious Adverse Events during Antituberculous Treatment in Rwanda: A Prospective Cohort Study
por: Lorent, Natalie, et al.
Publicado: (2011)

Gene expression profiling of whole blood in ipilimumab-treated patients for identification of potential biomarkers of immune-related gastrointestinal adverse events
por: Shahabi, Vafa, et al.
Publicado: (2013)

Ipilimumab and immune-mediated adverse events: a case report of anti-CTLA4 induced ileitis
por: Venditti, Olga, et al.
Publicado: (2015)

Surveillance of serious adverse events following immunization in resource poor settings
por: Breugelmans, Gabrielle J, et al.
Publicado: (2011)

Antipsychotics-Associated Serious Adverse Events in Children: An Analysis of the FAERS Database
por: Kimura, Goji, et al.
Publicado: (2015)

A Cancer Patient’s Experience With a Rare But Serious Adverse Event
por: RayChaudhury, Amlan
Publicado: (2019)

An HIV-infected Patient with No Serious Adverse Events after Overdosing on Raltegravir
por: Hosoda, Tomohiro, et al.
Publicado: (2019)

Association of Higher-Dose Fluoroquinolone Therapy With Serious Adverse Events in Older Adults With Advanced Chronic Kidney Disease
por: Muanda, Flory Tsobo, et al.
Publicado: (2022)

Serious Adverse Drug Events Reported to the FDA: Analysis of the FDA Adverse Event Reporting System 2006-2014 Database
por: Sonawane, Kalyani B., et al.
Publicado: (2018)

Immune-Mediated Adverse Events Associated with Ipilimumab CTLA-4 Blockade Therapy: The Underlying Mechanisms and Clinical Management
por: Tarhini, Ahmad
Publicado: (2013)

Retrospective Side Effect Profiling of the Metastatic Melanoma Combination Therapy Ipilimumab-Nivolumab Using Adverse Event Data
por: Soldatos, Theodoros G., et al.
Publicado: (2018)

Severe eosinophilia and subsequent dermatologic immune‐related adverse event with squamous cell carcinoma antigen elevation induced by nivolumab and ipilimumab
por: Matsumoto, Takeshi, et al.
Publicado: (2022)

Risk of cardiovascular serious adverse events associated with varenicline use for tobacco cessation: systematic review and meta-analysis
por: Prochaska, Judith J, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_b0mu71q3gb2jqa00fo12br210v